# Esa Pa Interpret Sit

> Interprets the saline infusion test (SIT) to assess the probability of primary aldosteronism when a patient has a positive aldosterone-to-renin ratio (ARR) and requires confirmatory testing. Triggers include evaluating post‑infusion plasma aldosterone concentration (PAC) after a positive ARR, hypertension work‑up, or when deciding whether to proceed to adrenal venous sampling (AVS).

- Skill: `dromlakhani/esa-pa-interpret-sit` (Agent Skill)
- Install (CLI): `npx skillmds add dromlakhani/esa-pa-interpret-sit`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/esa-pa-interpret-sit/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-08-19
- Page: https://skillmd.com/skills/dromlakhani/esa-pa-interpret-sit

---


# Interpret Saline Infusion Test for Primary Aldosteronism

## STEP 1 — Gather Information
- Obtain post‑infusion plasma aldosterone concentration (PAC) from the saline infusion test (2 L of 0.9% saline over 4 h, recumbent or seated).  
- Confirm baseline cortisol is lower than post‑infusion cortisol (for seated SIT) to exclude an ACTH effect.  
- Verify patient has a positive ARR, hypertension (sustained BP >150/100 mm Hg or resistant), and has discontinued mineralocorticoid receptor antagonists for ≥4 weeks.  
- Ensure no severe uncontrolled hypertension, cardiac arrhythmia, severe hypokalemia, or renal insufficiency that would contraindicate the test.

## STEP 2 — Rule In / Rule Out
- If post‑infusion PAC ≤ 5 ng/dL (≤ 140 pmol/L) → **rule out** primary aldosteronism (PA unlikely).  
- If post‑infusion PAC ≥ 10 ng/dL (≥ 280 pmol/L) → **rule in** primary aldosteronism (very probable PA).  
- If post‑infusion PAC is between 5 ng/dL and 10 ng/dL (140–280 pmol/L) → proceed to Step 3 (indeterminate range).

## STEP 3 — Classify or Stratify
- For indeterminate PAC (5–10 ng/dL), apply the cutoff of 6.8 ng/dL (190 pmol/L) that offers the best sensitivity/specificity trade‑off.  
- PAC < 6.8 ng/dL → lower probability of PA (consider repeat SIT or alternative confirmatory test).  
- PAC ≥ 6.8 ng/dL → higher probability of PA (proceed to subtype testing).

## STEP 4 — Decide
- PAC ≤ 5 ng/dL: Exclude PA; no further confirmatory testing needed; manage hypertension conventionally.  
- PAC ≥ 10 ng/dL: Diagnose PA; proceed to adrenal venous sampling (AVS) for lateralization and subtype classification.  
- PAC 5–10 ng/dL:  
  - If PAC < 6.8 ng/dL: Repeat SIT or perform fludrocortisone suppression test (FST) to clarify.  
  - If PAC ≥ 6.8 ng/dL: Proceed to AVS for lateralization.

## Clinical Guardrails / Mimics / Pitfalls
- Do not perform SIT in patients with severe uncontrolled hypertension, cardiac arrhythmia, severe hypokalemia, or renal insufficiency.  
- Avoid interpreting SIT without confirming adequate sodium status and withdrawal of interfering medications (MRAs, ACE‑I/ARBs, β‑blockers, NSAIDs) for at least 2–4 weeks.  
- Recumbent SIT has lower sensitivity; prefer seated SIT when available for better diagnostic accuracy.  
- Do not rely solely on SIT if baseline cortisol is not suppressed (risk of false‑positive due to ACTH surge).  
- Indeterminate results (5–10 ng/dL) should not be used to definitively rule in or out PA without additional testing.

## Concrete Clinical Example
A 48‑year‑old patient with resistant hypertension and a positive ARR undergoes a seated saline infusion test. Post‑infusion PAC measures 7.2 ng/dL (202 pmol/L). Since the value lies between 5–10 ng/dL, the 6.8 ng/dL cutoff is applied: PAC ≥ 6.8 ng/dL indicates higher probability of PA. The clinician proceeds to adrenal venous sampling for lateralization, which later confirms unilateral aldosterone‑producing adenoma.

**Source:** The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-4061